For over a decade, a group of food safety, environmental, and animal welfare nonprofits has petitioned the US Food and Drug ...

Elanco Animal Health (NYSE:ELAN) lost ~21% in the morning hours Thursday after the company updated on anticipated FDA approvals and market launch of its new products, Zenrelia and Credelio Quattro.

Elanco has submitted its response to the two questions in the letter, which did not require additional data generation. The FDA has offered a shortened, 60-day review timeline for Elanco’s response.

Additionally, due to the Food and Drug Administration’s black box warning on Elanco’s dermatology product Zenrelia, we expect a mild headwind on Elanco’s 2025 operating margin as the company ...

GREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a safe, highly ...

Additionally, due to the Food and Drug Administration’s black box warning on Elanco’s dermatology product Zenrelia, we expect a mild headwind on Elanco’s 2025 operating margin as the company ...

The U.S. Food and Drug Administration has approved a monthly chewable tablet for dogs made by Elanco Animal Health that ... Shares of Elanco edged up 0.5% in midmorning trading Tuesday, to $14.62 ...

FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic dermatitis. The drug, proven effective in studies, faces adoption challenges due ...

Boots suffered a stroke. That was determined by his veterinarian and Elanco, the maker of the drug, which paid for a portion of the care. Boots survived, but it took months of 24-hour care from ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a safe, highly effective, and convenient once-daily oral JAK ...